Predicting serious drug side effects before they occur

Mar 28, 2011

All medications have side-effects from common aspirin to herbal remedies and from standard anticancer drugs to experimental immunosuppressants. However, predicting important side effects, serious adverse drug reactions, ADRs, is with current understanding almost impossible. However, a neural network technology trained with past data could give drug companies and healthcare workers a new tool to spot the potential for ADRs with any given medication.

Writing in the International Journal of Medical Engineering and Informatics, at team from the University of Medicine and Dentistry of New Jersey, has developed a new model that tests show is 99.87 percent accurate in predicting among 10,000 observations and 100 percent for non-serious ADRs.

Peng-fang Yen and colleagues Dinesh Mital and Shankar Srinivasan explain how obligatory on medication packaging often serve only to cause concern among patients, while products withdrawn from the market because of repeated ADRs repeatedly undermine the pharmaceutical industry. From the medical industry's point of view and the perspective of patients, this is a growing concern that might be remedied with new technology, saving lives, reputations and healthcare costs.

The Food Drug Administration (FDA) in USA and the World Health Organization (WHO) monitor the safety of medications continuously. However, technology that could identify possible ADRs at the earliest possible stage of drug development, licensing and marketing is urgently needed, especially given the potential risks to patients in emerging areas of healthcare and the potential risks to shareholder confidence.

The team's artificial neural network is a of the biologic neural network embedded in computer software. It is trained by feeding in structural and physical data associated with known pharmaceutical products and any ADRs. A feedback loop discards those connections where a wrong prediction of a known outcome is made and as data are added the ANN builds up a network of correct "predictions". After sufficient training, the ANN can then be tested on another set of pharmaceuticals and outcomes checked against known ADRs. If confidence is sufficiently high, the ANN can be used to predict ADRs for new drugs.

The team has demonstrated an accuracy of 95 percent in preliminary tests and is now using a much larger data set of 10,000 drug molecules and ADR observations to train the ANN to a much more refined level.

Explore further: Gilead to license generic version of Sovaldi (Update)

More information: "Prediction of the serious adverse drug reactions using an artificial neural network model" in Int. J. Med. Eng. Informat., 2011, 3, 53-59

add to favorites email to friend print save as pdf

Related Stories

Danish children at risk from psychotropic medicines

Jun 22, 2010

Between 1998 and 2007, psychotropic medications were associated with 429 adverse drug reactions (ADRs) in children under 17 in Denmark. Researchers writing in the open access journal BMC Research Notes found that more than h ...

Recommended for you

Vaccine proves effective against deadly Middle East virus

Sep 15, 2014

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

Sep 15, 2014

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments : 0